欧普康视(300595) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 reached ¥286,936,799.16, representing a 175.99% increase compared to ¥103,967,367.36 in the same period last year[3] - Net profit attributable to shareholders was ¥138,104,771.92, a significant increase of 263.70% from ¥37,972,256.67 in the previous year[3] - Basic earnings per share rose to ¥0.2280, up 261.33% from ¥0.0631 in the previous year[3] - Operating profit for Q1 2021 was ¥167,592,165.71, a rise of 324.5% compared to ¥39,429,062.17 in the same quarter last year[34] - Net profit for Q1 2021 was ¥146,936,256.90, up 361.5% from ¥31,806,511.68 in Q1 2020[34] Cash Flow - The net cash flow from operating activities surged to ¥157,725,436.22, marking a 1,558.69% increase from ¥9,509,035.89 in the same period last year[3] - The net cash flow from investment activities was negative at -¥65,086,963.22, indicating increased financial management activities[15] - Cash flow from operating activities generated a net amount of CNY 157,725,436.22, compared to CNY 9,509,035.89 in the previous year, indicating a substantial improvement[39] - The total cash inflow from operating activities was CNY 322,330,675.15, compared to CNY 126,077,439.85 in the same quarter last year, reflecting a strong operational performance[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,539,360,687.66, an increase of 14.75% from ¥2,212,923,975.75 at the end of the previous year[3] - The company's total liabilities reached CNY 384,128,529.41, up from CNY 221,735,346.69, reflecting a significant increase of around 73.2%[28] - Current liabilities amounted to CNY 208,198,810.83, slightly down from CNY 209,819,798.92, showing a decrease of approximately 0.8%[28] - Total liabilities increased to ¥255,568,396.54, up 28.6% from ¥198,747,359.50 year-over-year[32] Investments and Expenses - R&D expenses rose to ¥6,933,902.94, a 97.52% increase from the previous year, indicating increased investment in research and development[13] - Investment income surged to ¥32,772,801.42, a 347.71% increase year-over-year, attributed to gains from subsidiary equity transfers and increased financial management returns[12] - The company’s tax expenses increased by 203.64% to ¥20,797,391.07, reflecting higher total profits[12] Shareholder Information - The net assets attributable to shareholders increased to ¥1,898,943,624.81, reflecting an 8.39% rise from ¥1,751,983,461.21 at the end of the previous year[3] - The top shareholder, Tao Yuequn, holds 35.14% of the shares, amounting to 213,493,449 shares[6] Operational Highlights - Major factors driving performance growth included strong product sales, increased revenue from marketing service terminals, effective control of operating expenses, and a rise in corporate income tax deductions[16] - The company completed the first registration of a Class II medical device product, fluorescein sodium ophthalmic test strips, during the reporting period[17] - The company has established long-term supply contracts with its main raw material supplier, Bausch & Lomb, to ensure supply stability[20] Risk Management - The company is addressing risks related to changes in national industry policies and product legal risks by implementing ISO13485 quality management systems and enhancing training and support for users[19] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[36]